Men and women living with chronic lymphocytic leukemia (CLL) have different quality-of-life (QoL) experiences depending on their treatment, according to new research.
Investigators in Isreal examined patients with CLL who were either undergoing active surveillance or targeted therapies. To understand treatment burden and any gender differences, patients in the study (n=210) were asked to complete the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire—the score was derived from the FACT-General (FACT-G) and leukemia-specific concerns (Leu-Subscale).
“In CLL, treatment initiation is deferred until clinical symptoms emerge, aiming to minimize treatment-related burden and maintain health-related QoL,” the investigators said.